[Whitepaper] The power of patient-centric digital approaches in orphan drug development and commercialization

In Orphan Drug Congress, Whitepapers by Freya Smale

Patients and their oftentimes sophisticated advocates continue to voice their needs and wants; which mostly center around the obvious – research for treatments and cures.

Download whitepaper now

“In an environment where scientists are many and trial participants are scarce, patient groups are starting to organize their own clinical trial networks and offer them to scientists because they realize their registries, their tissue banks, their biobanks, and their experience are the key resources.”

– Weisfeld W, English RA, Clairborne AB. Public Engagement and Clinical Trials: New Models and Disruptive

Download whitepaper now

Patient groups can be crucial to solving three primary challenges faced when developing orphan drugs:

  • Provide patient reported data, tissue samples, and natural histories;
  • Provide access to, and education for, constituents regarding clinical trial enrollment opportunities; and
  • Provide federally mandated patient guidance and input to clinical trial design

Patient engagement has been called the “blockbuster drug” of the 21st century.  No longer content to be bystanders in their own medical journey, today’s patients, particularly those with rare diseases, demand an interactive experience with the healthcare system and a voice in the development of management strategies as well as new treatments.

Whitepaper written by Dan Donovan & Tony Howell

We are thrilled to announce that one voice are joining us as a sponsor at this year’s World Orphan Drug Congress USA 2016. Register today to meet them in D.C. on April 20-22.

World Orphan Drug Congress USA 2016